Evaluation of the Safety and Effectiveness of BOTOX® (Botulinum Toxin Type A) in the Treatment of Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder: A Phase IV Non-interventional Post-marketing Surveillance Study in India

Trial Profile

Evaluation of the Safety and Effectiveness of BOTOX® (Botulinum Toxin Type A) in the Treatment of Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder: A Phase IV Non-interventional Post-marketing Surveillance Study in India

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 22 Apr 2017 Planned End Date changed from 1 Jun 2017 to 19 Sep 2017.
    • 22 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 8 Aug 2017.
    • 22 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top